Carbyne
Carbyne Equity Partners is a Hamburg-based private equity firm founded in 2023 that invests up to €150m in European Healthcare, Nutrition, and Agricultural Inputs businesses, backed by a single German entrepreneurial family as its sole LP.
- Company typePrivate
- Founded2023
- HeadquartersHamburg, Germany
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Carbyne does
Carbyne Equity Partners GmbH is a Hamburg-based private equity firm founded in 2023 that invests in growing European businesses with strong market positions. It operates a single-LP model backed by a German entrepreneurial family whose R&D-driven core activities span genetics, health, nutrition, and diagnostics. The firm focuses on three sectors — Healthcare, Nutrition, and Agricultural Inputs — and targets equity tickets of up to €150 million for buyouts and up to €50 million for growth equity, with platform investments in Europe and add-on investments permitted worldwide.
The firm generates revenue through two conventional PE streams: recurring management fees on committed capital from its LP base, and carried interest (performance fees) on profits from successful exits of portfolio companies. Its current portfolio comprises five named companies: ITM Isotope Technologies Munich SE (radiopharmaceutical biotech, co-invested with Temasek, BlackRock, QIA, Nextech, and ATHOS in 2023 with a renewed investment in 2024), Biomapas (pan-European pharma services / CRO, majority stake acquired October 2024), Elicit Plant (French agri-biotech biosolutions, minority stake November 2024), Chemia S.P.A. (Italian biologicals and crop protection under the Nutriland brand, majority stake November 2025), and SuanNutra (Madrid-based nutraceutical ingredients business acquired from Suanfarma in December 2025). The nine-person team is led by Managing Directors Dr. Markus Petersen and Alexander Winterling, supported by Investment Director Mai Karas and investment professionals with backgrounds in investment banking, consulting, and PE-backed operational roles.
Carbyne firmographics
Firmographics- Name
- Carbyne
- Legal name
- Carbyne Equity Partners GmbH
- Website
- https://carbynepartners.de
- Company type
- Private
- Founded year
- 2023
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Carbyne Equity Partners is a Hamburg-based private equity firm founded in 2023 that invests up to €150m in European Healthcare, Nutrition, and Agricultural Inputs businesses, backed by a single German entrepreneurial family as its sole LP.
- Ownership category
- akta.pro rank
Carbyne industry classification
Industry- Product category
- Private Equity Investment Services
- NAICS
- Portfolio Management and Investment Advice (52394), Other Investment Pools and Funds (5259), Other Financial Investment Activities (5239)
- SIC
- Investment Advice (6282), Security Brokers, Dealers & Flotation Companies (6211)
- akta.pro primary industry
- Carve-Out / Corporate Divestiture Buyout (FSANABAH)
- akta.pro secondary industries
- Family/Founder Succession Buyout (FSANABAK), Geography-Specialist Buyout (Regional/Country-Focused) (FSANABAF)
Keywords
Where Carbyne is headquartered
LocationHeadquarters
- HQ city
- Hamburg
- HQ country
- Germany
- HQ region
- Europe
Offices2 records
Markets served
Carbyne business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Technology or R&D, Marketing or Sales, Infrastructure
Revenue model
- Management Fees: As a private equity firm, Carbyne earns recurring management fees on committed capital from its limited partner (LP) base, which funds the operational running of the fund.
- Carried Interest (Performance Fees): Carbyne earns carried interest on profits from successful exits of portfolio companies, aligning the investment team's incentives with LP returns.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
Carbyne product offering
Product offeringCore offering
Carbyne Equity Partners is a private equity firm that invests in growing European businesses with strong market positions, focusing on three sectors: Healthcare, Nutrition, and Agricultural Inputs. The firm provides equity tickets up to €150m for buyouts and up to €50m for growth equity, sourced from a single German entrepreneurial family LP. It supports portfolio companies through operational expertise, add-on acquisitions, and the option of long-term integration with the family enterprise.
Product overview
Carbyne Equity Partners is a private equity firm that operates as a platform for investing in growing European businesses. Rather than a unified product architecture, the firm manages a diversified portfolio of portfolio companies across three core sectors: Healthcare (Biomapas, ITM), Nutrition (SuanNutra), and Agricultural Inputs (Chemia, Elicit Plant). The investment approach includes both majority and minority stakes, with equity tickets ranging from €50m for growth equity to €150m for buyouts. Portfolio companies retain their operational identities while benefiting from Carbyne's strategic support and family enterprise backing.
Differentiator
Problem solved
Functional benefit
Products and services
- Private Equity Investment Services Private equity investment services for European businesses with strong market positions across Healthcare, Nutrition, and Agricultural Inputs. Provides buyout equity tickets up to €150m and growth equity tickets up to €50m, with operational support and access to the founding family's network. Sourced and deployed through direct deal origination from founders, management teams, and intermediaries.
Quantifiable outcome
- One of the largest private investment rounds in European biotech (ITM investment with Temasek, BlackRock, QIA, Nextech, ATHOS)
- +1 more outcomes
Companies that use Carbyne
Customer profileSegments3 records
Ideal customer profiles3 records
Carbyne technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Carbyne partnerships and signals
Strategic signalScale indicators6 records
Recent moves6 records
Expansion highlights5 records
Carbyne competitors and assessment
Company assessmentDirect peers
- ARCHIMED: ARCHIMED is a European healthcare-focused private equity firm that previously owned SuanNutra (sold to Carbyne in Dec 2025). Both firms specialize in healthcare, life sciences, and nutrition ingredients investments across Europe with similar ticket sizes and sector specializations, making them direct peer firms.
- Gimv: Gimv is a Belgian-listed European private equity firm with deep specialization in Healthcare & Life Sciences. It makes similar mid-market equity tickets in European healthcare, life science services, and agri-tech companies, sharing Carbyne's sector and geographic focus.
- Avista Capital Partners: Avista Capital Partners is a healthcare-focused private equity firm investing in pharma services, specialty pharma, and MedTech companies. Its specialization in healthcare buyouts across the US and Europe makes it directly comparable to Carbyne's Healthcare vertical focus.
- Waterland Private Equity: Waterland is a European private equity firm with a strong healthcare and life sciences vertical alongside education and business services. It executes mid-market buyouts across Europe with sector specialization similar to Carbyne's three-vertical approach.
- Triton Partners: Triton Partners is a mid-market European private equity firm investing across healthcare, industrials, and business services with a sector-focused approach. Its European mid-market ticket sizes and operational support model are comparable to Carbyne's strategy.
- Deutsche Beteiligungs AG: Deutsche Beteiligungs AG is a German mid-market private equity firm providing buyout and growth capital to European industrial and services companies. As a German-headquartered firm with mid-market tickets, it competes with Carbyne for similar DACH-region opportunities.
- Bencis Capital Partners: Bencis is a European mid-market private equity firm headquartered in the Netherlands with sector specialization including healthcare and nutrition. It executes buyout transactions with similar ticket sizes and DACH/Benelux regional focus to Carbyne.
Broad incumbents
- Nordic Capital: Nordic Capital is a major European private equity firm with a dedicated Healthcare vertical covering pharma services, MedTech, and life sciences. As a much larger incumbent, it competes with Carbyne for similar European healthcare assets but operates across broader sectors with greater scale.
- EQT Private Capital (Healthcare): EQT is a major global private equity firm with a dedicated Healthcare sector team covering pharma services, MedTech, and life sciences in Europe. As a much larger broad incumbent, it competes with Carbyne for European healthcare assets with greater capital and broader sector coverage.
- Carlyle European Partners: Carlyle is a global private equity firm with significant European healthcare investing activity across pharma services, MedTech, and life sciences. As a broad incumbent, it competes with Carbyne for larger European healthcare assets with deeper resources and broader sector mandates.
Market position
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights6 records
Customer concentration
Carbyne social profiles
Digital presenceCarbyne financial estimates
Financial estimateRevenue estimate
Valuation estimate
Carbyne leadership team
Management profileNumber of profiles
Profiles8 records
Carbyne subsidiaries and ownership
Company hierarchySubsidiaries5 records
Carbyne funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Carbyne M&A and investment
M&A and investmentM&A1 record
Investments4 records
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Carbyne
What does Carbyne do?
Carbyne Equity Partners is a private equity firm that invests in growing European businesses with strong market positions, focusing on three sectors: Healthcare, Nutrition, and Agricultural Inputs. The firm provides equity tickets up to €150m for buyouts and up to €50m for growth equity, sourced from a single German entrepreneurial family LP. It supports portfolio companies through operational expertise, add-on acquisitions, and the option of long-term integration with the family enterprise.
Is Carbyne a public or private company?
Carbyne is a private company. It is classified as family owned and is currently operating.
When was Carbyne founded?
Carbyne was founded in 2023. It employs 1 to 10 people.
Where is Carbyne based?
Carbyne is headquartered in Hamburg, Germany, in the Europe region.
How does Carbyne make money?
Two revenue lines are on record. Management Fees are the primary driver. The others are carried Interest (Performance Fees).
Who are Carbyne's main competitors?
Direct peers on record are ARCHIMED, Gimv, Avista Capital Partners, Waterland Private Equity, Triton Partners, Deutsche Beteiligungs AG and Bencis Capital Partners. Broad incumbents are Nordic Capital, EQT Private Capital (Healthcare) and Carlyle European Partners.
Does Carbyne have an API?
No public API is recorded for Carbyne.
What industry is Carbyne in?
Carbyne's product category is Private Equity Investment Services. Its primary akta.pro industry code is FSANABAH, Carve-Out / Corporate Divestiture Buyout, with a secondary code of FSANABAK, Family/Founder Succession Buyout. Its NAICS code is 52394 and its SIC code is 6282.